1-20 of 28
Brian T. Hess
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies

Clinical Trials & Observations
James A. Davis, Katelynn Granger, Kiera Roubal, Deidra Smith, Kelly J. Gaffney, Mary McGann, Alyssa Cendagorta, Aswani Thurlapati, Amanda Herbst, Lindsey Hendrickson, Hamza Hashmi, Brian T. Hess
Journal: Blood
Blood (2023) 141 (2): 200–203.
https://doi.org/10.1182/blood.2022018283
Published: 2023
Journal Articles

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy

Joanna Zurko, Geoffrey Shouse, Pallawi Torka, Tamara K. Moyo, Jason T. Romancik, Imran A. Nizamuddin, Kaitlin Annunzio, Jieqi Liu, Stefan K. Barta, Robert Ferdman, Rahul Bhansali, Jonathon B. Cohen, Sayan Mullick Chowdhury, Nirav N. Shah, Elyse I. Harris, Vaishalee P. Kenkre, McKenzie Sorrell, Brian T. Hess, Deborah M. Stephens, Lindsey A. Fitzgerald, Thomas A. Ollila, Ishan Roy, Shuo Ma, Jane N. Winter, Barbara Pro, Jonathan Moreira, Leo I. Gordon, Alexey V Danilov, Andrew M. Evens, Narendranath Epperla, Reem Karmali
Journal: Blood
Blood (2022) 140 (Supplement 1): 375–377.
https://doi.org/10.1182/blood-2022-163438
Published: 2022
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Hun Ju Lee, Jeremy S. Abramson, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch, Domingo Domenech Eva, Brian T. Hess, Steven R. Schuster, Yuliya Linhares, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Giuseppe Rossi, Uwe H Hahn, Henry Miles Prince, Linda Ho, Wenchuan Guo, Christopher A. Yasenchak, David J. Straus
Journal: Blood
Blood (2022) 140 (Supplement 1): 9399–9401.
https://doi.org/10.1182/blood-2022-156576
Published: 2022
Journal Articles

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Reem Karmali, Narendranath Epperla, Geoffrey Shouse, Jason T. Romancik, Tamara K. Moyo, Vaishalee P. Kenkre, Thomas A. Ollila, Lindsey A. Fitzgerald, Brian T. Hess, Andrew M. Evens, Ishan Roy, Joanna Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul Bhansali, Elyse I. Harris, McKenzie Sorrell, Jieqi Liu, Imran A. Nizamuddin, Shuo Ma, Jonathan Moreira, Jane N. Winter, Barbara Pro, Deborah M. Stephens, Alexey V Danilov, Nirav N. Shah, Jonathon B. Cohen, Stefan K. Barta, Pallawi Torka, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 10955–10957.
https://doi.org/10.1182/blood-2022-160431
Published: 2022
Journal Articles

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Juan Pablo Alderuccio, Russ A Kuker, Isildinha M Reis, Muthiah Nachiappan, Brad S. Kahl, Mehdi Hamadani, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Brian T. Hess, Matthew A. Lunning, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Eric Yu, Paolo F Caimi, Deukwoo Kwon, Izidore S. Lossos, Fei Yang, Craig H. Moskowitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 6650–6652.
https://doi.org/10.1182/blood-2022-162758
Published: 2022
Journal Articles

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Ishan Roy, Narendranath Epperla, Geoffrey Shouse, Jason T. Romancik, Tamara K. Moyo, Vaishalee P. Kenkre, Thomas A. Ollila, Lindsey A. Fitzgerald, Brian T. Hess, Andrew M. Evens, Joanna Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S. Bhansali, Elyse I. Harris, McKenzie Sorrell, Jieqi Liu, Imran A. Nizamuddin, Jonathan Moreira, Shuo Ma, Jane N. Winter, Barbara Pro, Deborah M. Stephens, Alexey V Danilov, Nirav N. Shah, Jonathon B. Cohen, Stefan K. Barta, Pallawi Torka, Leo I. Gordon, Reem Karmali
Journal: Blood
Blood (2022) 140 (Supplement 1): 2416–2418.
https://doi.org/10.1182/blood-2022-163822
Published: 2022
Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Alex F. Herrera, Stephen M. Ansell, Pier Luigi Zinzani, John Radford, Kami J. Maddocks, Antonio Pinto, Graham P. Collins, Veronika Bachanova, Nancy L. Bartlett, Isabelle Bence-Bruckler, Mehdi Hamadani, Justin Kline, Jiri Mayer, Kerry J. Savage, Ranjana H. Advani, Paolo F. Caimi, René-Olivier Casasnovas, Tatyana A. Feldman, Brian T. Hess, Mariana Bastos-Oreiro, Sunil Iyengar, Árpád Szomor, William Townsend, Marc Andre, Jerzy Dyczkowski, Sandy Eisen, Andrzej Urban, Serafino Pantano, Hans G. Cruz, Luqiang Wang, Yanina Negievich, Jens Wuerthner, Carmelo Carlo-Stella
Journal: Blood
Blood (2022) 140 (Supplement 1): 3673–3677.
https://doi.org/10.1182/blood-2022-157583
Published: 2022
Journal Articles

A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)

Brian T. Hess, Graham P. Collins, Melhem Solh, Mitul Gandhi, Ying Wang, Yajuan Qin, Eric Yu, Pier Luigi Zinzani
Journal: Blood
Blood (2022) 140 (Supplement 1): 12079–12080.
https://doi.org/10.1182/blood-2022-163277
Published: 2022
Journal Articles

Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy

Jennifer L. Crombie, Robert A. Redd, Victor A. Chow, Jordan Gauthier, Erin Mullane, Geoffrey Shouse, Alex F. Herrera, Jason Romancik, Jonathon B. Cohen, Anna Saucier, Roch Houot, Caron Jacobson, Philippe Armand, Brian T. Hess
Journal: Blood
Blood (2021) 138 (Supplement 1): 886.
https://doi.org/10.1182/blood-2021-152819
Published: 2021
Journal Articles

Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

Joanna C. Zurko, Narendranath Epperla, Imran Nizamuddin, Pallawi Torka, Kevin A. David, Thomas A. Ollila, Brian T. Hess, Jonathon B. Cohen, Robert Ferdman, Jieqi Liu, Sayan Mullick Chowdhury, Kaitlyn O'Shea, Jason Romancik, Rahul Bhansali, Elyse Harris, Mckenzie Sorrell, Rebecca Masel, Lindsey Fitzgerald, Carlos Galvez, Shuo Ma, Jane N. Winter, Barbara Pro, Leo I. Gordon, Alexey V. Danilov, Deborah M. Stephens, Nirav N. Shah, Geoffrey Shouse, Vaishalee P. Kenkre, Stefan K. Barta, Reem Karmali
Journal: Blood
Blood (2021) 138 (Supplement 1): 884.
https://doi.org/10.1182/blood-2021-147433
Published: 2021
Journal Articles

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

Imran Nizamuddin, Kevin A. David, Jonathon B. Cohen, Vaishalee P. Kenkre, Geoffrey Shouse, Brian T. Hess, Thomas A. Ollila, Deborah M. Stephens, Sayan Mullick Chowdhury, Robert Ferdman, Kaitlyn O'Shea, Jieqi Liu, Jason T. Romancik, Joanna C. Zurko, Rahul S. Bhansali, Elyse I. Harris, McKenzie Sorrell, Rebecca Masel, Lindsey Fitzgerald, Carlos Galvez, Shuo Ma, Jane N. Winter, Barbara Pro, Leo I. Gordon, Alexey V. Danilov, Nirav N. Shah, Stefan K. Barta, Narendranath Epperla, Pallawi Torka, Reem Karmali
Journal: Blood
Blood (2021) 138 (Supplement 1): 532.
https://doi.org/10.1182/blood-2021-147033
Published: 2021
Journal Articles

Phase I Study of Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Brian T. Hess, Leandro Cerchietti, Lindsey Hendrickson, Elizabeth Hill, Anshu Giri, Shanta Salzer, Sarah Hogan, Lacey Finch, Robin Klingenberg, Fang Hu, Nina D. Wagner-Johnston
Journal: Blood
Blood (2021) 138 (Supplement 1): 3567.
https://doi.org/10.1182/blood-2021-145493
Published: 2021
Journal Articles

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial

Juan Pablo Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3575.
https://doi.org/10.1182/blood-2021-148730
Published: 2021
Journal Articles

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Paul A. Hamlin, Manish R. Patel, Don Stevens, Brian T. Hess, Javier Munoz, Tatyana A. Feldman, Sonali M. Smith, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Stephen D. Smith
Journal: Blood
Blood (2021) 138 (Supplement 1): 2423.
https://doi.org/10.1182/blood-2021-148313
Published: 2021
Journal Articles

A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

Sushanth Gouni, Allison C. Rosenthal, Jennifer L. Crombie, Andrew Ip, Manali Kamdar, Brian T. Hess, Lei Feng, Grace Watson, Amy Ayers, Sattva S. Neelapu, Arushi Khurana, Madiha Iqbal, Yi Lin, Reid W Merryman, Paolo Strati
Journal: Blood
Blood (2021) 138 (Supplement 1): 2495.
https://doi.org/10.1182/blood-2021-147591
Published: 2021
Journal Articles

Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma

Brian T. Hess, MD, Anshu Giri, MD, Yeonhee Park, PhD, Krina K. Patel, MD, Brian K. Link, MD, Grzegorz S. Nowakowski, MD, Seth M Maliske, MD, Sonia Fortin, Julio C. Chavez, MD, Hayder Saeed, MD, Brian T. Hill, MD, Alex V. Mejia Garcia, MD, Kami J. Maddocks, MD, Walter Hanel, MD, Nina D. Wagner-Johnston, Marcus Raymond Messmer, MD, Brad S. Kahl, MD, Marcus Watkins, PhD, Juan Pablo Alderuccio, MD, Izidore S. Lossos, MD, Sunita Nathan, MD, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Daniel J. Landsburg, MD, Emily C. Ayers, MD, Jorge J. Castillo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-138536
Published: 2020
Journal Articles

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paolo F Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, MD, Kirit M. Ardeshna, Mehdi Hamadani, MD, Brian T. Hess, MD, Brad S. Kahl, MD, John A. Radford, MD FMedSci, Melhem Solh, MD, Anastasios Stathis, MD, Pier Luigi Zinzani, MD, Jay Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo-Stella, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–37.
https://doi.org/10.1182/blood-2020-137524
Published: 2020
Journal Articles

Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Yazeed Sawalha, MD, Subir Goyal, PhD, Jeffrey M. Switchenko, PhD MS, Jason T. Romancik, MD, Manali Kamdar, MD, Irl Brian Greenwell, MD, Brian T. Hess, MD, Krista Isaac, DO,MS, Craig A. Portell, MD, Alex V. Mejia Garcia, MD, Scott R. Goldsmith, MD, Natalie S Grover, MD, Peter A. Riedell, MD, Reem Karmali, MDMSc, Madelyn Burkart, MD, Michael J Buege, PharmD, Othman S. Akhtar, MD, Pallawi Torka, MD, Anita Kumar, MD, Brian T. Hill, MD, Brad S. Kahl, MD, Jonathon B. Cohen, MDMS
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–6.
https://doi.org/10.1182/blood-2020-138878
Published: 2020
Journal Articles

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Carmelo Carlo-Stella, MD, Graham P. Collins, MD DPhil, Kami J. Maddocks, MD, Nancy L. Bartlett, MD, Kerry J. Savage, MDMSc, Paolo F Caimi, Brian T. Hess, MD, Pier Luigi Zinzani, MD, Hans G Cruz, Luqiang Wang, Jay Feingold, Jens Wuerthner, Stephen M. Ansell, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-137451
Published: 2020
Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 466.
https://doi.org/10.1182/blood-2019-123986
Published: 2019